Despite the recent identification of a number of Mycobacterium leprae proteins, the major immunogenic determinants of this organism remain obscure. We isolated from M. leprae a potent immunostimulatory preparation, designated the MLP fraction, which contains a major protein of 35 kilodaltons (kDa). This protein was precipitated by monoclonal antibody ML03-A,, which recognizes a 35-kDa protein of M. leprae, and by sera obtained from patients with lepromatous leprosy. Neither sera from healthy controls nor sera from patients with pulmonary tuberculosis recognized the 35-kDa protein, and only one of four serum samples from patients with borderline tuberculoid leprosy reacted with this protein. The MLP fraction stimulated T-cell proliferation in patients with leprosy whose T cells proliferate in response to whole M. leprae cells. Apparently, the T-cell epitope associated with MLP is also expressed on M. tuberculosis and M. bovis BCG, since patients with pulmonary tuberculosis and BCG-vaccinated individuals demonstrated significant responses to the MLP fraction. The 35-kDa M. leprae protein, purified to homogeneity in the laboratory of P. J. Brennan, stimulated T-cell proliferative responses in all MLP-responsive subjects. These findings suggest that the 35-kDa protein present in MLP is an immunostimulatory component of M. leprae. In addition to serving as a useful probe for study of the T-cell anergy associated with lepromatous disease, this protein may ultimately be useful as a component of a vaccine designed to provide protection against infection with M. leprae.
were kindly provided by Luiz M. Bermudez, Medical Research Institute, San Francisco, Calif. Control serum was obtained from a healthy individual never exposed to leprosy bacilli and known to be a nonresponder to M. leprae. The rabbit polyclonal antibodies used were serum pools from two animals immunized with the M. Ieprae protein fraction (MLP) recovered from the pellet fraction of sonicated M. leprae as described below. Rabbit anti-M. bovis BCG polyclonal antibodies were kindly provided by P. J. Brennan. Murine MAb ML03-A1, which identifies a 35-kDa M. leprae protein, and MAb F47-CL9, which binds to a 36-kDa M. leprae protein (15; Engers et al., Letter), were kindly provided by Thomas Shinnick, Centers for Disease Control, Atlanta, Ga.
Surface phenotype analysis of T cells. Murine MAbs to CD3 (anti-Leu-4), CD8 (anti-Leu-2), and CD4 (anti-Leu-3) were generated in our laboratory and purified from ascites. Fluorescein-conjugated antibodies were prepared as described earlier (34) . Analysis of surface phenotypes with these antibodies was performed on an Ortho System 50H Cytofluorograf (34) .
Preparation of MLP. The MLP fraction containing the 35-kDa protein was recovered from the pellet fraction of sonicated M. leprae. Briefly, lyophilized bacilli were rehydrated with phosphate-buffered saline (PBS; pH 7.0) and washed once by centrifugation. Bacilli (33 mg/ml of PBS) were sonicated on ice for a total of 3 min, with 20-s bursts followed by 10-s rests, in a W-10 probe sonicator (Heat System-Ultrasonics, Inc., Plainview, N.Y.). The sonic extract was then centrifuged at 25,000 x g. The supernatant containing soluble sonicated proteins (SS) was removed, and the pellet was washed twice with PBS. To remove the lipid moiety, the pellet was suspended in PBS and cold acetone was added dropwise to a concentration of 60% (vol/vol). After 2 h of incubation at 4°C, this suspension was centrifuged at 25,000 x g and the resultant pellet was dried under vacuum for 4 h. Subsequently, the pellet was suspended in 1.0 ml of PBS and the soluble fraction designated the MLP fraction was collected by centrifugation at 25,000 x g. The protein concentration of the MLP fraction was measured by the Folin reagent. Thereafter, the material was divided into aliquots and stored at -70°C until used. Lyophilized, uninfected armadillo liver was subjected to an identical fractionation procedure, and the final supernatant was used as a control (control protein) in the studies described below.
Protein analysis by SDS-PAGE. M. leprae SS, the MLP fraction, and the purified 35-kDa protein (10 ,ug of protein per lane) were reduced in 5% ,-mercaptoethanol and run on SDS-10% PAGE gels as described by Laemmli (21) . The protein bands were silver stained under basic pH conditions (38) ered from SDS-PAGE gels by the method described by Young and Lamb (39) . Briefly, 15 ,ug of the MLP fraction was fractionated by SDS-10% PAGE. Proteins were then transferred from the gel to nitrocellulose by electroblotting with a Trans-Blot cell apparatus (Bio-Rad). To allow for accurate localization of protein, prestained molecular size markers ranging from 15 to 206 kDa (Bethesda Research Laboratories, Inc., Gaithersburg, Md.) were used. Each nitrocellulose strip (6 by 35 mm) was divided into 16 equal sections which were tested separately for the ability to stimulate T-cell proliferation. Sections of nitrocellulose strips which contained no protein were added to the control cultures.
RESULTS
Preparation and characterization of MLP. The MLP fraction and SS were prepared from sonicated leprosy bacilli as described in Materials and Methods. From 100 mg of M. leprae, approximately 150 p.g of the MLP fraction and 5.5 mg of SS were obtained. SDS-PAGE analysis of the MLP fraction (10 ,ug) under reducing conditions, followed by silver staining, revealed a major band of 35 kDa and several minor bands in the 70-and 12-to 18-kDa ranges (Fig. 1 , lane c). These minor bands appeared more prominently in SDS-PAGE of SS together with multiple additional bands dispersed throughout the gel (Fig. 1, lane a) . SDS-PAGE of an identically treated sonic extract of armadillo liver cells obtained from uninfected animals (control protein) revealed several bands in the 70-kDa and 18-to 30-kDa ranges; however, it did not reveal a band in the region of 35 kDa (Fig. 1, lane b) .
The dominant (35-kDa) protein in the MLP fraction was recognized by MAb ML03-A1, which is known to react with a 35-kDa protein of M. Ieprae (7, 12, 14) (Fig. 2A, lane a) . In addition to the 35-kDa protein, MAb ML03-A1 reacted with a minor band of 70 kDa. The same 35-and 70-kDa bands were precipitated by rabbit polyclonal antibodies to the MLP fraction and by pooled sera from four patients with LL ( Fig (Fig. 2B , lane e). Similarly, neither rabbit anti-M. bovis polyclonal antibodies nor serum from a healthy control reacted with the 35-kDa protein ( Fig. 2A, lanes b and e) . Figure 3 shows the results of immunoabsorption of the 125I-labeled MLP fraction with individual sera from a panel of patients. Only one of four sera from patients with BTL (lanes d to g) reacted weakly with the 35-kDa protein (lane f). In addition, serum from this patient revealed a minor band of 70 kDa. By contrast, sera from all four patients with LL reacted with the major 35-kDa protein of the MLP fraction, as well as the antigen corresponding to the 70-kDa protein (Fig. 3, lanes h to k) . Sera from the nine patients with PT tested, however, did not react with the MLP fraction. Representative data are shown in Fig. 2B (lane c) and 3 (lane 1).
Responses of T cells to the MLP fraction. To test for the presence of T-cell-stimulating epitopes, the MLP fraction was used in proliferation assays. Initially, we compared the abilities of MLP and whole M. leprae cells to stimulate PBL from patients with BTL over a wide dose range. Data from these experiments are shown in Fig. 4 . The MLP fraction at concentrations of 0.5 to 1 ,ug/ml induced proliferation comparable to that elicited by 10 ,ug of whole M. leprae cells per ml in PBL from patients with BTL. Increasing the concentration of MLP to 10 ,ug/ml resulted in profound reduction of proliferation in two of the three PBL samples tested ( Fig. 4A and E). Control protein from armadillo liver cells, however, ,sg/ml 10 did not produce significant stimulation (SI, <2), indicating that the proliferative response to the MLP fraction is not due to contaminating xenogeneic antigens (Fig. 4A, B, and D (Fig. 5) . Thus, the profiles of the responses of nonresponder patients with LL to the MLP fraction and intact leprosy bacilli were identical.
To determine whether the MLP fraction possesses T-cell epitopes common to other mycobacteria, the ability of T cells from patients with PT (Fig. 5) . PBL from the two healthy blood donors that responded to the MLP fraction and whole M. leprae cells by proliferation (Fig. 5) were also responsive to M. tuberculosis (data not shown). Taken together, these findings indicate that the MLP fraction is devoid of nonspecific mitogenic activity and an epitope(s) associated with a protein(s) contained in the MLP fraction is recognized by T cells of M. leprae responder patients with leprosy, patients with PT, and healthy individuals who respond to mycobacterial antigens.
Next, studies were performed to determine whether a panel of M. leprae-reactive CD4+ T-cell clones were capable of responding to the MLP fraction. These clones were generated by stimulating CD4+ T cells of two patients with BTL (patients 1 and 2) and one patient with LL (patient 3) with sonicated M. leprae in the presence of autologous or human lymphocyte antigen-identical APC. Of (Fig. 6) . The possibility exists that additional proteins present in the MLP preparation are capable of eliciting a T-cell response but failed to do so because they could not be recovered in sufficient quantity from SDS-PAGE. Even if such proteins were present in our preparation, however, the analysis of T-cell-stimulating activity recoverable from SDS-PAGE suggests that the 35-kDa protein present in the MLP fraction is a potent T-cell immunogen.
To address this question further, the 35-kDa protein purified to homogeneity from M. leprae bacilli by P. J. Brennan was tested for its ability to react with MAb ML03-A1 and activate T cells from patients with BTL. MAb ML03-A1 precipitated the purified 35-kDa protein (Fig. 7,  lane b) the native proteins from the pellet fraction of sonicated leprosy bacilli. This preparation, designated MLP, contains a major protein with a molecular mass of 35 kDa on the basis of SDS-PAGE analysis (Fig. 1) . In studies of sera from patients with LL, who characteristically have high levels of 6 . Stimulation of PBL with proteins recovered from MLP preparation by SDS-PAGE. PBL from two patients with BTL were cultured for 6 days with SDS-PAGE-separated, nitrocellulosebound fractions (16 fractions) of the MLP preparation. Proliferation was measured as described in Materials and Methods. Localization of proteins was determined by using prestained molecular size markers. The response of PBL from patient A to 10 ,Lg whole M. leprae cells per ml in the presence of nitrocellulose was 7,363 ± 1,088 cpm, and the response of PBL from patient B was 22,995 ± 793 cpm; the background uptakes were 1,150 and 600 cpm, respectively. (Fig. 8) We considered the possibility that a protein other than the 35-kDa polypeptide present in the MLP preparation was responsible for the observed T-cell stimulation. Initial studies designed to address this question showed that within the MLP preparation, a protein(s) of approximately 35 kDa was the only detectable T-cell stimulus (Fig. 6) . In a final series of experiments, the 35-kDa protein purified to homogeneity from leprosy bacilli was examined for its ability to stimulate T-cell responses in MLP-reactive subjects. The results showed that the purified protein was recognized by MAb ML03-A1 (Fig. 7) , which is known to react with a 35-kDa protein of M. leprae (7, 12, 14) and the MLP fraction and that this protein stimulates T-cell responses (Fig. 8) . We have not ruled out the possibility that lipopolysaccharide comigrating with the 35-kDa protein contributes to the observed T-cell response to the MLP fraction. However, other investigators (5, 6, 17, 33) , as well as our group (Mohagheghpour, unpublished data) , have failed to detect any T-cell responses to mycobacterium-derived lipopolysaccharides, including lipoarabinomannan B of M. leprae. Moreover, previous studies have demonstrated that lipoarabinomannan B nonspecifically inhibits T-cell reactions (6, 17) .
Antibody competition studies by Mwatha et al. (28) confirm our findings that the 35-kDa protein is a strong B-cell immunogen. Using MAb ML04, which binds to an epitope expressed by the 35-kDa protein of M. leprae and has paratope specificities similar to those of ML03 (15) , those investigators found that essentially all patients with LL but no healthy subjects from the leprosy-endemic area produced high levels of antibodies to the 35- The failure of T cells from most patients with LL to respond to whole M. Ieprae cells (2, 11, 26) , is thought to be a major contributing factor both to the massive accumulation of M. leprae organisms in the skin of patients with LL and to the aggressive clinical course which characterizes these patients. Therefore, our finding that the same patients whose In addition to serving as a probe in studies of the mechanism of M. Ieprae-specific T-cell anergy, the immunogenicity of the 35-kDa protein observed in convalescent patients with BTL suggests that this protein may be a useful component in a vaccine designed to provide protection against infection with leprosy bacilli. The fact that this antigen is recognized by the T cells of BCG-vaccinated individuals, as well as patients with leprosy, does not necessarily detract from its potential efficacy as a leprosy vaccine. Indeed, recent evidence suggests that the protective antigens of mycobacteria are those which are shared by other mycobacterial species rather than species-specific antigens (35) (36) (37) . Studies with a murine model of leprosy support this possibility, as immunization of mice with the MLP fraction protected them from subsequent infection with leprosy bacilli (9) .
